Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Non-Current Assets for 16 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 32.84% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.8 million, a 25.37% decrease, with the full-year FY2024 number at $1.4 million, down 11.58% from a year prior.
  • Non-Current Assets was $1.1 million for Q3 2025 at Plus Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.9 million in Q1 2021 to a low of $1.1 million in Q3 2025.
  • A 5-year average of $1.9 million and a median of $1.8 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: dropped 0.05% in 2024, then crashed 37.99% in 2025.
  • Plus Therapeutics' Non-Current Assets stood at $2.7 million in 2021, then decreased by 22.73% to $2.0 million in 2022, then decreased by 24.2% to $1.6 million in 2023, then decreased by 11.58% to $1.4 million in 2024, then decreased by 21.11% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Non-Current Assets are $1.1 million (Q3 2025), $1.1 million (Q2 2025), and $1.2 million (Q1 2025).